Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chia

Showing results (21-30 of 104) with videos related to

Pageof 11
Sort By:
Health and Quality of Life Outcomes|November 30, 2011
The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severitiesPaulos Teckle, Stuart Peacock, Helen McTaggart-Cowan, et al.
Journal of Comparative Effectiveness Research|August 29, 2025
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancerStephen Chia, Jie Li, Fei Ma, et al.
Genes, Chromosomes & Cancer|April 22, 2004
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinomaNikita Makretsov, May He, Malcolm Hayes, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian PerspectiveJan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to ExplainDaniel Rayson, Sonal Gandhi, Anil A Joy, et al.
CMAJ Open|August 1, 2014
Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort studyAshley Davidson, Stephen Chia, Robert Olson, et al.
Current Oncology (Toronto, Ont.)|January 28, 2021
Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?Sheina A Macadam, Karen Slater, Rona E Cheifetz, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895"Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Breast Cancer Research : BCR|July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA studyAndreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancerAndreas Schneeweiss, Stephen Chia, Tamas Hickish, et al.
Pageof 11

Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
Health and Quality of Life Outcomes|November 30, 2011
The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severitiesPaulos Teckle, Stuart Peacock, Helen McTaggart-Cowan, et al.
Journal of Comparative Effectiveness Research|August 29, 2025
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancerStephen Chia, Jie Li, Fei Ma, et al.
Genes, Chromosomes & Cancer|April 22, 2004
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinomaNikita Makretsov, May He, Malcolm Hayes, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian PerspectiveJan-Willem Henning, Christine Brezden-Masley, Karen Gelmon, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to ExplainDaniel Rayson, Sonal Gandhi, Anil A Joy, et al.
CMAJ Open|August 1, 2014
Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort studyAshley Davidson, Stephen Chia, Robert Olson, et al.
Current Oncology (Toronto, Ont.)|January 28, 2021
Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?Sheina A Macadam, Karen Slater, Rona E Cheifetz, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891-9895"Daniel Rayson, Sonal Gandhi, Anil A Joy, et al.
Breast Cancer Research : BCR|July 10, 2014
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA studyAndreas Schneeweiss, Stephen Chia, Roberto Hegg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancerAndreas Schneeweiss, Stephen Chia, Tamas Hickish, et al.
Pageof 11